Localization of metallothionein in breast carcinomas. An immunohistochemical study

Manuel Fresno, Weiyu Wu, Jose M. Rodriguez, Mehrdad Nadji

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Metallothionein (MT) is a cysteine-rich, low molecular weight protein that binds zinc, copper, and cadmium. It is present in a number of normal cells including hepatocytes particularly during fetal and early postnatal life. It has been suggested that developmental profile of MT is similar to other oncofetal gene products and hence, it could be used as a marker for aggressive tumour behaviour. In order to test that hypothesis, we used a monoclonal antibody to MT and immunohistochemically evaluated formalin-fixed, paraffin-embedded tissues from 79 breast carcinomas. In non-neoplastic breast tissue, a strong nuclear and cytoplasmic staining was observed in myoepithelial cells. Positive staining for MT was present in 35 (44%) of breast carcinomas. In most positive cases, nuclear, or both nuclear and cytoplasmic staining was seen. All positive tumours were invasive ductal carcinomas, including a medullary and a metaplastic carcinoma. None of the mucinous, lobular, or intraductal papillary carcinomas reacted for MT. A statistically significant association was found between MT immunostaining and histological grade (P<0.01) as well as with nuclear grade (P<0.01). We also observed an inverse relationship between MT staining and oestrogen receptor content of tumours (P<0.01). Similarly, a statistically significant association was found between moderate and strong MT immunostainig and decreased overall survival and shorter disease-free survival (P<0.01). MT immunostaining was also predective of a worse prognosis in the subgroup of lymph node negative (P<0.001) and oestrogen receptor negative patients (P<0.01). No statistically significant association was found between MT staining and size of tumour or the presence of lymph node metastasis. We conclude that MT staining may be a useful marker of less differentiated and more aggressive carcinomas of the breast.

Original languageEnglish
Pages (from-to)215-219
Number of pages5
JournalVirchows Archiv A Pathological Anatomy and Histopathology
Volume423
Issue number3
DOIs
StatePublished - May 1 1993

Fingerprint

Metallothionein
Breast Neoplasms
Staining and Labeling
Estrogen Receptors
Lymph Nodes
Neoplasms
Ductal Carcinoma
Carcinoma, Intraductal, Noninfiltrating
Papillary Carcinoma
Tumor Biomarkers
Cadmium
Paraffin
Formaldehyde
Disease-Free Survival
Cysteine
Zinc
Copper
Hepatocytes
Breast
Cell Count

Keywords

  • Breast cancer
  • Immunohistochemistry
  • Metallothionein

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Anatomy

Cite this

Localization of metallothionein in breast carcinomas. An immunohistochemical study. / Fresno, Manuel; Wu, Weiyu; Rodriguez, Jose M.; Nadji, Mehrdad.

In: Virchows Archiv A Pathological Anatomy and Histopathology, Vol. 423, No. 3, 01.05.1993, p. 215-219.

Research output: Contribution to journalArticle

@article{c4ba4409117f4e3988a01844274321e8,
title = "Localization of metallothionein in breast carcinomas. An immunohistochemical study",
abstract = "Metallothionein (MT) is a cysteine-rich, low molecular weight protein that binds zinc, copper, and cadmium. It is present in a number of normal cells including hepatocytes particularly during fetal and early postnatal life. It has been suggested that developmental profile of MT is similar to other oncofetal gene products and hence, it could be used as a marker for aggressive tumour behaviour. In order to test that hypothesis, we used a monoclonal antibody to MT and immunohistochemically evaluated formalin-fixed, paraffin-embedded tissues from 79 breast carcinomas. In non-neoplastic breast tissue, a strong nuclear and cytoplasmic staining was observed in myoepithelial cells. Positive staining for MT was present in 35 (44{\%}) of breast carcinomas. In most positive cases, nuclear, or both nuclear and cytoplasmic staining was seen. All positive tumours were invasive ductal carcinomas, including a medullary and a metaplastic carcinoma. None of the mucinous, lobular, or intraductal papillary carcinomas reacted for MT. A statistically significant association was found between MT immunostaining and histological grade (P<0.01) as well as with nuclear grade (P<0.01). We also observed an inverse relationship between MT staining and oestrogen receptor content of tumours (P<0.01). Similarly, a statistically significant association was found between moderate and strong MT immunostainig and decreased overall survival and shorter disease-free survival (P<0.01). MT immunostaining was also predective of a worse prognosis in the subgroup of lymph node negative (P<0.001) and oestrogen receptor negative patients (P<0.01). No statistically significant association was found between MT staining and size of tumour or the presence of lymph node metastasis. We conclude that MT staining may be a useful marker of less differentiated and more aggressive carcinomas of the breast.",
keywords = "Breast cancer, Immunohistochemistry, Metallothionein",
author = "Manuel Fresno and Weiyu Wu and Rodriguez, {Jose M.} and Mehrdad Nadji",
year = "1993",
month = "5",
day = "1",
doi = "10.1007/BF01614773",
language = "English",
volume = "423",
pages = "215--219",
journal = "Virchows Archiv",
issn = "0945-6317",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Localization of metallothionein in breast carcinomas. An immunohistochemical study

AU - Fresno, Manuel

AU - Wu, Weiyu

AU - Rodriguez, Jose M.

AU - Nadji, Mehrdad

PY - 1993/5/1

Y1 - 1993/5/1

N2 - Metallothionein (MT) is a cysteine-rich, low molecular weight protein that binds zinc, copper, and cadmium. It is present in a number of normal cells including hepatocytes particularly during fetal and early postnatal life. It has been suggested that developmental profile of MT is similar to other oncofetal gene products and hence, it could be used as a marker for aggressive tumour behaviour. In order to test that hypothesis, we used a monoclonal antibody to MT and immunohistochemically evaluated formalin-fixed, paraffin-embedded tissues from 79 breast carcinomas. In non-neoplastic breast tissue, a strong nuclear and cytoplasmic staining was observed in myoepithelial cells. Positive staining for MT was present in 35 (44%) of breast carcinomas. In most positive cases, nuclear, or both nuclear and cytoplasmic staining was seen. All positive tumours were invasive ductal carcinomas, including a medullary and a metaplastic carcinoma. None of the mucinous, lobular, or intraductal papillary carcinomas reacted for MT. A statistically significant association was found between MT immunostaining and histological grade (P<0.01) as well as with nuclear grade (P<0.01). We also observed an inverse relationship between MT staining and oestrogen receptor content of tumours (P<0.01). Similarly, a statistically significant association was found between moderate and strong MT immunostainig and decreased overall survival and shorter disease-free survival (P<0.01). MT immunostaining was also predective of a worse prognosis in the subgroup of lymph node negative (P<0.001) and oestrogen receptor negative patients (P<0.01). No statistically significant association was found between MT staining and size of tumour or the presence of lymph node metastasis. We conclude that MT staining may be a useful marker of less differentiated and more aggressive carcinomas of the breast.

AB - Metallothionein (MT) is a cysteine-rich, low molecular weight protein that binds zinc, copper, and cadmium. It is present in a number of normal cells including hepatocytes particularly during fetal and early postnatal life. It has been suggested that developmental profile of MT is similar to other oncofetal gene products and hence, it could be used as a marker for aggressive tumour behaviour. In order to test that hypothesis, we used a monoclonal antibody to MT and immunohistochemically evaluated formalin-fixed, paraffin-embedded tissues from 79 breast carcinomas. In non-neoplastic breast tissue, a strong nuclear and cytoplasmic staining was observed in myoepithelial cells. Positive staining for MT was present in 35 (44%) of breast carcinomas. In most positive cases, nuclear, or both nuclear and cytoplasmic staining was seen. All positive tumours were invasive ductal carcinomas, including a medullary and a metaplastic carcinoma. None of the mucinous, lobular, or intraductal papillary carcinomas reacted for MT. A statistically significant association was found between MT immunostaining and histological grade (P<0.01) as well as with nuclear grade (P<0.01). We also observed an inverse relationship between MT staining and oestrogen receptor content of tumours (P<0.01). Similarly, a statistically significant association was found between moderate and strong MT immunostainig and decreased overall survival and shorter disease-free survival (P<0.01). MT immunostaining was also predective of a worse prognosis in the subgroup of lymph node negative (P<0.001) and oestrogen receptor negative patients (P<0.01). No statistically significant association was found between MT staining and size of tumour or the presence of lymph node metastasis. We conclude that MT staining may be a useful marker of less differentiated and more aggressive carcinomas of the breast.

KW - Breast cancer

KW - Immunohistochemistry

KW - Metallothionein

UR - http://www.scopus.com/inward/record.url?scp=0027381677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027381677&partnerID=8YFLogxK

U2 - 10.1007/BF01614773

DO - 10.1007/BF01614773

M3 - Article

C2 - 8236816

AN - SCOPUS:0027381677

VL - 423

SP - 215

EP - 219

JO - Virchows Archiv

JF - Virchows Archiv

SN - 0945-6317

IS - 3

ER -